Form 13-F position report

NUVALENT INC

Reported by Bain Capital Life Sciences Investors LLC

Company profile Manager portfolio Source filing
NUVL CUSIP 670703107 Manager CIK 0001703031
Latest reported change

Reported 1,447,267 shares, unchanged from the prior quarter.

Reported value -9.4%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 15.19% This manager · Q1 2025
Shares 1,447,267 Quarter-end amount reported
Reported value $102,640,176 Fair value at quarter end
Consecutive quarters held 15 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q3 2025 Reduced 0 -1,447,267 (-100.0%) 0 $0 2025-11-14
Q2 2025 Unchanged 1,447,267 0 (0.0%) 13.82% $110,426,472 2025-08-14
Q1 2025 Unchanged 1,447,267 0 (0.0%) 15.19% $102,640,176 2025-05-15
Q4 2024 Reduced 1,447,267 -1,250,000 (-46.3%) 13.33% $113,292,061 2025-02-14
Q3 2024 Unchanged 2,697,267 0 (0.0%) 28.71% $275,930,414 2024-11-14
Q2 2024 Unchanged 2,697,267 0 (0.0%) 22.46% $204,614,675 2024-08-12
Q1 2024 Reduced 2,697,267 -880,000 (-24.6%) 16.28% $202,537,779 2024-05-15
Q4 2023 Unchanged 3,577,267 0 (0.0%) 25.23% $263,251,079 2024-02-13
Q3 2023 Unchanged 3,577,267 0 (0.0%) 18.39% $164,446,964 2023-11-14
Q2 2023 Unchanged 3,577,267 0 (0.0%) 15.54% $150,853,349 2023-08-14
Q1 2023 Unchanged 3,577,267 0 (0.0%) 11.66% $93,331,000 2023-05-15
Q4 2022 Added 3,577,267 +149,253 (4.4%) 11.9% $106,531,000 2023-02-14
Q3 2022 Unchanged 3,428,014 0 (0.0%) 7.95% $66,641,000 2022-11-14
Q2 2022 Unchanged 3,428,014 0 (0.0%) 5.45% $46,484,000 2022-08-15
Q1 2022 Unchanged 3,428,014 0 (0.0%) 4.62% $47,615,000 2022-05-16
Q4 2021 Unchanged 3,428,014 0 (0.0%) 5.18% $65,269,000 2022-02-14
Q3 2021 New 3,428,014 +3,428,014 (0.0%) 4.8% $77,302,000 2021-11-15
Institutional context

Who else reported the position

243 managers reported NUVALENT INC for Q1 2025.

Manager Activity Shares Change % of reported 13F Reported value Tenure
DEERFIELD MANAGEMENT COMPANY L P SERIES C Unchanged 17,991,024 0 25.19% $1,275,923,422 15 qtrs
FMR LLC Added 9,937,193 +282,867 0.04% $704,745,718 15 qtrs
Paradigm Biocapital Advisors LP Reduced 5,269,433 -93,946 17.12% $373,708,188 8 qtrs
VANGUARD GROUP INC Reduced 4,439,838 -60,026 < 0.01% $314,873,311 15 qtrs
BlackRock Inc Reduced 3,748,361 -103,216 < 0.01% $265,833,762 3 qtrs
COMMODORE CAPITAL LP Added 1,855,000 +233,400 9.69% $131,556,600 10 qtrs
PERCEPTIVE ADVISORS LLC Reduced 1,633,968 -986,009 4.09% $115,881,011 15 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 1,450,602 +152,692 0.01% $102,878,000 10 qtrs
Bain Capital Life Sciences Investors LLC This report Unchanged 1,447,267 0 15.19% $102,640,176 15 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 1,442,384 +157,809 0.02% $102,293,874 15 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 15, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,447,267
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.